GSK update on Bexxar

"My own guess is that probably we will have an advisory committee" to review the non-Hodgkin's lymphoma therapy Bexxar (iodine I 131 tositumomab) once Corixa has responded to FDA's March "complete review" letter for the product, GlaxoSmithKline VP-New Product Development James Palmer tells Goldman Sachs healthcare conference June 13. "We are working closely with Corixa, dealing with the questions. That is going very well, and we would expect to probably get to the next stage in the second half of this year. There will have to be a decision about whether there is an advisory committee or not. It is speculative right now"